SORRENTO THERAPEUTICS
Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal can... cer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.
SORRENTO THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.sorrentotherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
(858) 210-3759
Email Addresses:
[email protected]
Total Funding:
264.42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-07-07 | Ancora Medical Technology | Ancora Medical Technology acquired by Sorrento Therapeutics | N/A |
| 2021-04-05 | ACEA Therapeutics | ACEA Therapeutics acquired by Sorrento Therapeutics | 38 M USD |
| 2020-07-24 | SmartPharm Therapeutics | SmartPharm Therapeutics acquired by Sorrento Therapeutics | N/A |
| 2016-08-15 | Semnur Pharmaceuticals | Semnur Pharmaceuticals acquired by Sorrento Therapeutics | N/A |
| 2016-08-08 | Scilex Pharmaceuticals | Scilex Pharmaceuticals acquired by Sorrento Therapeutics | N/A |
Investors List
Ally Bridge Group
Ally Bridge Group investment in Post-IPO Equity - Sorrento Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-08-05 | Aardvark Therapeutics | Sorrento Therapeutics investment in Series B - Aardvark Therapeutics | 29 M USD |
| 2021-07-19 | Celularity | Sorrento Therapeutics investment in Post-IPO Equity - Celularity | 80 M USD |
| 2018-02-15 | Celularity | Sorrento Therapeutics investment in Venture Round - Celularity | 250 M USD |
| 2015-01-31 | Globavir | Sorrento Therapeutics investment in Venture Round - Globavir | 4 M USD |
| 2015-01-01 | NantiBodyFc | Sorrento Therapeutics investment in Private Equity Round - NantiBodyFc | 10 M USD |
Official Site Inspections
http://www.sorrentotherapeutics.com Semrush global rank: 868.79 K Semrush visits lastest month: 43.24 K
- Host name: 147.108.198.104.bc.googleusercontent.com
- IP address: 104.198.108.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
